105 related articles for article (PubMed ID: 15494771)
1. Should the implantable cardiac defibrillator be used for primary prevention of sudden death? A review of the issues relevant to hospital decision making.
McGregor M; Chen J
Can J Cardiol; 2004 Oct; 20(12):1199-204. PubMed ID: 15494771
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age.
Sanders GD; Kong MH; Al-Khatib SM; Peterson ED
Am Heart J; 2010 Jul; 160(1):122-31. PubMed ID: 20598982
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
[TBL] [Abstract][Full Text] [Related]
4. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
[TBL] [Abstract][Full Text] [Related]
5. Cost of preimplantation cardiac imaging in patients referred for a primary-prevention implantable cardioverter-defibrillator.
Krahn AD; Hoch JS; Rockx MA; Leong-Sit P; Gula LJ; Yee R; Skanes AC; Klein GJ
Am J Cardiol; 2008 Sep; 102(5):588-92. PubMed ID: 18721517
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
[TBL] [Abstract][Full Text] [Related]
7. Preventing sudden death: implantable cardioverter-defibrillators in elderly cardiac patients.
Groeneveld PW
LDI Issue Brief; 2008; 13(6):1-4. PubMed ID: 18613344
[TBL] [Abstract][Full Text] [Related]
8. The Italian Implantable Cardioverter-Defibrillator Registry. A survey of the national activity during the years 2001-2003.
Proclemer A; Ghidina M; Cicuttini G; Gregori D; Fioretti PM
Ital Heart J; 2005 Mar; 6(3):272-80. PubMed ID: 15875520
[TBL] [Abstract][Full Text] [Related]
9. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
10. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
Zwanziger J; Hall WJ; Dick AW; Zhao H; Mushlin AI; Hahn RM; Wang H; Andrews ML; Mooney C; Wang H; Moss AJ
J Am Coll Cardiol; 2006 Jun; 47(11):2310-8. PubMed ID: 16750701
[TBL] [Abstract][Full Text] [Related]
11. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the implantable cardioverter defibrillator.
Hlatky MA; Sanders GD; Owens DK
Card Electrophysiol Rev; 2003 Dec; 7(4):479-82. PubMed ID: 15071279
[TBL] [Abstract][Full Text] [Related]
13. Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.
Filion KB; Xie X; van der Avoort CJ; Dendukuri N; Brophy JM
Int J Technol Assess Health Care; 2009 Apr; 25(2):151-60. PubMed ID: 19331707
[TBL] [Abstract][Full Text] [Related]
14. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
[TBL] [Abstract][Full Text] [Related]
15. Sudden death prior to pediatric heart transplantation: would implantable defibrillators improve outcome?
Rhee EK; Canter CE; Basile S; Webber SA; Naftel DC
J Heart Lung Transplant; 2007 May; 26(5):447-52. PubMed ID: 17449412
[TBL] [Abstract][Full Text] [Related]
16. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
17. End-user involvement in health technology assessment (HTA) development: a way to increase impact.
McGregor M; Brophy JM
Int J Technol Assess Health Care; 2005; 21(2):263-7. PubMed ID: 15921068
[TBL] [Abstract][Full Text] [Related]
18. Primary prevention of sudden cardiac death: can we afford the cost of cardioverter-defibrillators? Data from the Search-MI Registry-Italian sub-study.
Boriani G; Biffi M; Russo M; Lunati M; Botto G; Proclemer A; Vergara G; Rahue W; Martignani C; Ricci R; Santini M;
Pacing Clin Electrophysiol; 2006 Dec; 29 Suppl 2():S29-34. PubMed ID: 17169130
[TBL] [Abstract][Full Text] [Related]
19. Costs and quality-of-life effects of implantable cardioverter-defibrillators.
Groeneveld PW; Matta MA; Suh JJ; Heidenreich PA; Shea JA
Am J Cardiol; 2006 Nov; 98(10):1409-15. PubMed ID: 17134641
[TBL] [Abstract][Full Text] [Related]
20. The high cost of implantable defibrillators.
Hlatky MA; Mark DB
Eur Heart J; 2007 Feb; 28(4):388-91. PubMed ID: 17032689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
